澳门广东会贵宾厅

CN
News & Reports

News and Reports

Select year

2025 2024 2023 2022 2021 Earlier
shown/page
5
5 10 15 20

2025.07.31

Chipscreen Biosesciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
Chipscreen Biosesciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Full text

2024.10.17

Chipscreen Biosesciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosesciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

Full text

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

Full text

2024.04.30

National Medical Products Administration (NMPA) Approves Chipscreen Biosescience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
National Medical Products Administration (NMPA) Approves Chipscreen Biosescience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

Full text

2024.03.18

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

Full text
Media contact

Media contact

  • Media contact

    （+86）0755-36993500

  • Media contact

    pr@deatoo.com

澳门广东会贵宾厅